A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

NCT ID: NCT04735575

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-20
• Study Completion Date: 2024-08-20

Brief Summary

The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.

Detailed Description

This is a Phase I/II, multi-center, open label, multiple-dose, first in human study, designed to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for EMB-06 in patients with relapsed or refractory multiple myeloma. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

Conditions

Relapsed or Refractory Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

EMB-06

In Phase I part: participants enrolled at different time will receive EMB-06 by IV infusion at different ascending dose levels.

In Phase II part: participants will receive EMB-06 by IV infusion at previously defined RP2D.

Group Type: EXPERIMENTAL

EMB-06

Intervention Type: BIOLOGICAL

EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.

Interventions

EMB-06

EMB-06 is a FIT-Ig® bispecific antibody against BCMA and CD3.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Able to understand and willing to sign the informed consent form (ICF)
• Patients who have been diagnosed with multiple myeloma according to IMWG diagnostic criteria 2014 and have relapsed or refractory multiple myeloma with at least one measurable lesion.
• The patient must have received at least two lines (for patients in the US, at least three lines which should include anti-CD38 antibody) of prior antimyeloma therapies, and must have received treatment with proteasome inhibitors, immunomodulatory agents, and if accessible, an anti-CD38 targeting monoclonal antibody.
• ECOG performance status 0 or 1 for phase I, and ≤2 for phase II.
• Adequate organ function and reasonable laboratory test results to participate in the trial.
• Highly effective contraception

Exclusion Criteria

• Life expectancy is less than 3 months.
• Patient participated in any other clinical study within 1 month prior to enrollment in this clinical study.
• Patients with ongoing AE.
• Previously treated with any BCMA-targeted therapy.(Exception: in Phase 2 portion, up to 10 patients who have received prior anti-BCMA ADC or BCMA targeted CAR-T can be enrolled)
• History of allogeneic stem cell transplantation.
• Previously treated with the following anti-tumor therapy (prior to first dosing of EMB-06)

1. Treated with monoclonal antibody for multiple myeloma within 28 days

2. Treated with proteasome inhibitors within 14 days

3. Treated with immunomodulatory agents within 14 days

4. Treated with cytotoxic therapy within 14 days

5. Received investigational drug within 28 days or at least 5 half-lives, whichever is shorter (if a, b, c, d not applicable)

6. Received radiotherapy within 21 days. Except that the radiation portal covered ≤ 5% of the bone marrow reserve, the patient will be eligible to participate in the study regardless of the end date of radiation therapy

7. Plasmapheresis within 7 days

• Patient received autologous stem cell transplantation within 12 weeks prior to the start of study treatment.
• Active or historically multiple myeloma related central nervous system involvement.
• Patients requiring high dose of systemic treatment with corticosteroids.
• Patients with active infections, including COVID-19, hepatitis, etc..
• History of severe allergic reactions
• Patients with severe or uncontrolled cardiovascular disorder requiring treatment
• Pre-existing other serious medical conditions

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai EpimAb Biotherapeutics Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sunshine Coast Haematology and Oncology Clinic (SCHOC)

Buderim, Queensland, Australia

Epworth Healthcare

Richmond, Victoria, Australia

One Clinical Research (OCR)

Nedlands, Western Australia, Australia

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Peking University, Third Hospital

Beijing, , China

Guangdong Provincial People's Hospital

Guangzhou, , China

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, , China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, , China

Henan Cancer Hospital

Zhengzhou, , China

Countries

Australia; China

Other Identifiers

EMB06X101

Identifier Type: -

Identifier Source: org_study_id